[Asia Economy Reporter Minji Lee] Geoen announced on the 23rd that it has independently developed an antiviral filter capable of responding to the novel coronavirus infection (COVID-19).


The virus blocking performance of the antiviral filter was verified through experiments conducted last month at the Biology Laboratory of Sogang University. The virus used in this experiment was a lentivirus, a highly toxic virus well known as the Human Immunodeficiency Virus (HIV), which causes Acquired Immune Deficiency Syndrome (AIDS).


The experiment was conducted over a total of seven trials. A 1 mL virus solution, concentrated to the maximum, was aerosolized using a nebulizer and passed through the antiviral filter at a speed more than 50% faster than the rate at which a person breathes through a mask. The experiment measured the extent to which the virus in the collected solution infected cells.


A Geoen official stated, “In the control experiment without the antiviral filter, a large amount of lentivirus was detected, whereas after passing through the filter, virus detection was almost nonexistent. Similar results were obtained in all seven trials, and the average virus blocking performance of the antiviral filter was 98.6%. The reliability of this experiment is over 99.9%.”


As a result of requesting filter analysis from the Korea Testing & Research Institute (KATR), Geoen’s antiviral filter was found to not only block viruses but also kill pneumonia bacteria and food poisoning bacteria with an efficiency of over 99.9%.



A Geoen official added, “It can block the transmission of pathogens through the air from virus-infected patients or pneumonia patients to others. Additionally, Geoen’s filter does not contain any harmful heavy metal ions or nanoparticles such as copper or silver nanoparticles, which can be fatal to the respiratory system, nor does it contain any substances that cause allergies.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing